BioTransplant, MedImmune Inc. deal

The companies will develop products to treat and prevent organ rejection using MEDI's anti-T cell receptor antibody MEDI-500 and BioTransplant's BTI-322 antibody. MEDI received worldwide exclusive rights to develop and commercialize BTI-322, BioTransplant's antibody to reverse organ rejection in kidney transplant patients.

BioTransplant (Charlestown, Mass.) received a $2 million license fee, and may receive up to $14 million in milestones and research support. MEDI (Gaithersburg, Md.) will fund and assume responsibility for clinical testing and commercialization of resulting products. BioTransplant will receive royalties on sales of both products and future products. ...